

Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of mTOR Signaling in Interstitial Macrophages and Myofibroblasts

Guochun Chen^{1,2*}, Huihui Chen³, Chang Wang^{1,2}, Youming Peng^{1,2}, Lin Sun^{1,2}, Hong Liu^{1,2}, Fuyou Liu^{1,2*}

1 Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China, **2** Kidney Research Institute of Central South University, Changsha, Hunan, P.R. China, **3** Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China

Abstract

Interstitial fibrosis is an inevitable outcome of all kinds of progressive chronic kidney disease (CKD). Emerging data indicate that rapamycin can ameliorate kidney fibrosis by reducing the interstitial infiltrates and accumulation of extra cellular matrix (ECM). However, the cellular mechanism that regulates those changes has not been well understood yet. In this study, we revealed the persistent activation of mammalian target of rapamycin (mTOR) signaling in the interstitial macrophages and myofibroblasts, but rarely in injured proximal epithelial cells, CD4+ T cells, neutrophils, or endothelial cells, during the development of kidney fibrosis. Administration of rapamycin to unilateral ureteral obstruction (UUO) mice significantly suppressed the immunoreactivity of mTOR signaling, which decreased the inflammatory responses and ECM accumulation in the obstructed kidneys. Isolated macrophages from rapamycin-treated obstructed kidneys presented less inflammatory activity than vehicle groups. In vitro study confirmed that rapamycin significantly inhibited the fibrogenic activation of cultured fibroblasts (NIH3T3 cells), which was induced by the stimulation of TGF- β_1 . Further experiment revealed that rapamycin did not directly inhibit the fibrogenesis of HK2 cells with aristolochic acid treatment. Our findings clarified that rapamycin can ameliorate kidney fibrosis by blocking the mTOR signaling in interstitial macrophages and myofibroblasts.

Citation: Chen G, Chen H, Wang C, Peng Y, Sun L, et al. (2012) Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of mTOR Signaling in Interstitial Macrophages and Myofibroblasts. PLoS ONE 7(3): e33626. doi:10.1371/journal.pone.0033626

Editor: Bernhard Ryffel, French National Centre for Scientific Research, France

Received: November 4, 2011; **Accepted:** February 14, 2012; **Published:** March 28, 2012

Copyright: © 2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by the Foundation of the Ministry of Education of China for Outstanding Young Teachers in University (200805331032) to Dr. Guochun Chen, the Research Award Fund for Young Teachers in Central South University (2011QNZT165) to Dr. Guochun Chen and National Natural Science Foundation of China (30871169) to Dr. Fuyou Liu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: chenguochun@hotmail.com (GC); lfy410@yahoo.com.cn (FL)

Introduction

Tubulointerstitial fibrosis is the final common pathway of a wide variety of chronic progressive kidney diseases. Intense studies have focused on the molecular and cellular pathogenesis of interstitial fibrosis due to the strong correlation between the degree of interstitial fibrosis and renal functional loss in CKD. Recently, studies in a wide variety of animal models confirmed that treatment of rapamycin to inhibit mTOR could markedly ameliorate the interstitial inflammation, fibrosis, and loss of renal function associated with CKD [1–7]. However, little has been clarified in these studies upon the cellular targets of rapamycin, regarding its protective role in kidney fibrosis.

Progression of renal fibrosis can initially be characterized as induction of inflammatory response and ultimately result in widespread fibrotic changes. Multiple cell types within the interstitium, including kidney resident cells and infiltrates from circulation, directly contribute to the induction of inflammatory cascade and the fibrogenic process as a source of various proinflammatory and profibrotic molecules [8–10]. To date, the regulatory mechanism in these effector cells still remains obscure in kidney fibrosis, which limits the prevention and early interruption in the disease development.

mTOR is a major effector of cell growth and protein synthesis via the direct functional control of its downstream targets, ribosomal protein S6 kinase (S6k) and eukaryotic initiation factor 4E-binding protein-1 (4EBP-1) [11]. Recently, novel regulation of mTOR signaling has been identified in various pathological conditions, including activation of macrophages [12,13] and myofibroblasts [14–16], indicating the importance of mTOR in the regulation of kidney fibrosis. However, it is unclear which cell types have mTOR activation and where rapamycin works on during the development of kidney fibrosis.

In this study, we looked into each specific cell type in the kidney to evaluate the role of rapamycin in renal fibrosis. We characterized the activation pattern of mTOR signaling in different renal cell types during kidney injury-fibrosis; we also evaluated the effect of rapamycin on the fibrogenic activity of cultured fibroblasts, HK2 cells and macrophages isolated from the fibrotic kidneys.

Materials and Methods

Ethics statement

All experiments were performed in accordance with the animal experimental guidelines issued by the Animal Care and Use

Committee at Xiangya Medical School of Central South University. This study was approved by the Animal Care and Use Committee of the 2nd Xiangya Hospital (protocol approval number 2008-S 062).

Animals

C57BL/6 mice were obtained from the animal facility in the 2nd Xiangya hospital and maintained under specific pathogen-free conditions. Rapamycin (2 mg/kg·day) (LC laboratories, Woburn, USA) was administered to a subgroup of UO mice by daily intraperitoneal injections starting one day prior to surgery and continuing until termination of the experiment.

Induction of kidney injury in mice

Female C57BL/6 mice aged 8–10 weeks weighing 20–22 g were used for induction of kidney injury. In brief, ischemia-reperfusion-injury (IRI) was induced by the retroperitoneal approach on both kidneys for 28 min at 37°C (moderate IRI). One milliliter of warm saline (37°C) was injected intraperitoneally after surgery for volume supplement. Sham operations were performed with exposure of both kidneys but without induction of ischemia. To generate the UO mice, the left kidney and ureter were exposed via a flank incision. The ureter was ligated at two points proximal to the kidney with 6–0 silk. The wound was closed in layers. Sham animals had kidney exposed but ureter was not tied.

Kidney tissue preparation

Mice were anesthetized, sacrificed and immediately perfused via the left ventricle with ice-cold PBS for 2 min. Kidneys were hemi-sectioned and portions were snap frozen in liquid nitrogen for later western blot and real-time qPCR analysis. Some kidneys were fixed in 10% neutral buffered formalin at 4°C for 12 hr, processed, embedded in paraffin wax, sectioned in 4 µm and stored at room temperature for use. Some kidneys were fixed in 4% PLP fixative (4% paraformaldehyde, 75 mM L-lysine, 10 mM sodium periodate) for 4 hr at 4°C, cryoprotected in 30% sucrose and snap frozen in optimal cutting temperature (OCT, Sakura FineTek). Frozen kidneys were sectioned in 7 µm for immunofluorescent staining.

Renal histological analysis

Kidney paraffin sections were stained with hematoxylin-eosin (HE) using standard procedures. HE-stained paraffin sections were assessed by quantitative measurement of tubular injury in 10

individual high-power fields (magnification ×400) per kidney. A percentage of the area affected was estimated for the number of necrotic cells, loss of brush border, cast formation, and tubule dilation as follows: 0, 0 to 5%; 1, 5 to 10%; 2, 11 to 25%; 3, 26 to 45%; 4, 46 to 75%, and 5, >76%. The matrix score for collagen-I deposition in the renal cortical interstitium was determined by procedures in accordance with previous reports [17]. The fields analyzed in each section were selected randomly. Ten separate, nonoverlapping microscopic fields of each kidney section were averaged to yield the score of each kidney. The scores for 3–6 separate animals for each group were then averaged.

Immunofluorescence and immunohistochemical staining

All stainings of kidney were performed on 4 µm paraffin sections or 7 µm cryosections as previously described [18]. In brief, cryosections were air-dried for 15 min, then primary antibodies against the following proteins were used: pS6K (rabbit, 1:100, Cell signaling, USA), F4/80 (rat, 1:100, Abcam, USA), CD3 (rabbit 1:100, Vectorlab, USA), CD4 (mouse, 1:100, Abcam, USA), anti-neutrophil (rat, 1:50, Santa Cruz, USA), αSMA (mouse, 1:200, Abcam, USA), collagen-I (rabbit, 1:500, Abcam, USA), Kim-1 (goat, 1:100, R&D, USA), Lotus tetragonolobus lectin (LTL, 1:1000, Vectorlab, USA). The slides were then exposed to FITC (1:200) or Cy3-labeled (1:500) secondary antibodies (Jackson ImmunoResearch, USA). Sections were mounted in Vectashield medium containing DAPI (Invitrogen, USA). Representative images were taken with confocal microscopes (Leica TCS SP5).

Immunohistochemical stains were performed on formalin fixed, paraffin embedded 4 µm sections. Sections were rehydrated and antigens retrieved using heated citrate. Incubation of primary antibodies was performed same as described above. Staining was visualized using horseradish-peroxidase coupled secondary antibodies (Vectastain elite, Vector Labs).

Related isotype immunoglobulins (Jackson ImmunoResearch, USA) were used as negative controls in all stainings. All immunohistochemical analyses were repeated at least three times and representative images were presented.

Isolation of F4/80+ macrophages from obstructed kidneys

At day 1 post-obstruction, kidneys derived from either vehicle or rapamycin-treated groups were harvested, minced, and homogenized, followed by incubation with 0.1% collagenase (Worthington, USA) and 20 g/ml DNase I (Qiagen, USA) for 30 min at 37°C. Following the manufacture's instruction, mononuclear cells

Table 1. Applied Primers for Real-time qPCR.

Genes	GenBank accession	Sense primers (5' – 3')	Anti-sense primers (5' – 3')
CXCL1	NM_008176	CTGGGATTACCTCAAGAATC	CAGGGTCAAGGCAAGCCTC
IL-1β	NM_008361	GAAATGCCACCTTTTGACAGTG	CTGGATGCTCTCATCAGGACA
MCP-1	NM_011333	TAAAAACCTGGATCGGAACCAAA	GCATTAGCTTCAGATTACGGGT
TNF-α	NM_013693	CAGGCGGTGCCTATGTCTC	CGATCACCCCGAAGTTAGTAG
CTGF	NM_010217	GACCCAACTATGATGCGAGCC	TCCCACAGGTCTTAGAACAGG
TGF-β ₁	NM_011577	GAGCCCGAAGCGGACTACTA	GTTGTTGCGGTCCACCATT
Col1α2	NM_007743	AGCTTTGTGGATACGCGGAC	TAGGCACGAAGTTACTGCAAG
GAPDH	NM_008084	AGGTCGGTGTGAACGGATTG	GGGGTCGTTGATGGCAACA

Abbreviations: CXCL1 - chemokine (C-X-C motif) ligand 1, IL-1β - interleukin 1 beta, MCP-1 - chemokine (C-C motif) ligand 2, TNF-α - tumor necrosis factor alpha, CTGF - connective tissue growth factor, TGF-β₁ - transforming growth factor beta 1, Col1α2 - collagen type 1 alpha 2, GAPDH - glyceraldehyde-3-phosphate dehydrogenase. doi:10.1371/journal.pone.0033626.t001

were obtained by density separation using Lympholyte M (Cedarlane, USA). Macrophages were labeled with biotin-conjugated rat anti-mouse F4/80, purified and enriched using MACS (Miltenyi Biotec). Total RNA was extracted from enriched F4/80 macrophages and reverse transcribed for real-time qPCR analysis of gene expression.

Cell culture and immunocytochemical staining

The NIH 3T3 fibroblast cell line and HK2 cell line from ATCC (American Type Culture Collection) were cultured in DMEM medium supplemented with 10% FBS until the cells were 80%

confluent. Cells were then incubated in DMEM medium containing 0.2% FBS for 24 hr. NIH3T3 cells and HK2 cells were cultured for 24 to 48 hr in the presence of 10 ng/ml recombinant human TGF- β_1 (PeproTech, NJ, USA) or 5 μ g/ml aristolochic acid (AA, Sigma), with or without addition of 50 nmol rapamycin (LC lab, MA, USA) for 12 hr. Portions of NIH3T3 cells and HK2 cells were cultured in four-chamber glass and immunocytochemical staining was performed as previously described [18]. In brief, Cells were fixed and blocked before immunocytochemical staining. Cells were then incubated in primary antibodies (including α SMA and pS6K) at 4°C overnight,




Figure 1. Assessment of immunoreactivity of mTOR signaling in normal and pathological kidneys. Kidney tissues derived from wide type C57BL/6J mice, moderate IRI and UUO mouse models were used for analysis. Animals were treated as described in Methods. A(A')–C(C'): Costaining of pS6K (red) and LTL (green) in renal sections from post-natal day 1 (P1, A: low-power and A': high-power), post-natal day 7 (P7, B: low-power and B': high-power), 6-week (6w, C) and 16-week mice (16w, C'). D–F: Representative costaining images of pS6K (red) and LTL (green) in kidney sections derived from moderate IRI mice, including 48-hour (IR-48 hr, D), 7-day (IR-7d, E) and 2-week (IR-2w, F) after operation. G–I: Representative costaining images of pS6K (red) and LTL (green) in kidney sections derived from UUO models, including 1-day (U1d, G), 3-day (U3d, H) and 7-day (U7d, I) post-obstruction. J: Western blot and quantitative analysis of p-mTOR and pS6K in developing kidneys (right panel), moderate IRI model (middle panel) and UUO model (left panel). n = 5 animals in each group. *P < 0.05, **P < 0.01, NS, no significance. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g001

followed by incubation in secondary antibodies consisting of anti-rabbit-Cy3 and anti-mouse-FITC. After rinsing in PBS, slides were mounted with Vectashield mounting medium containing DAPI (Invitrogen) and visualized under a confocal microscope (Leica TCS SP5). All immunocytochemical analyses were repeated 3 or more times and related isotype immunoglobulins were used as negative controls.

Western blot analysis

Lysates of kidney or cultured cells were prepared as previously described [19]. Membranes were incubated with the following primary antibodies, respectively: rabbit antibody to p-mTOR and pS6K (Cell signaling, 1 in 1000), mouse antibody to α SMA and vimentin (Abcam, 1:1000), rabbit antibody to collagen-I (Abcam, 1:1000). β -actin-specific antibody (Abcam, 1:1000) was used for loading controls on stripped membranes. Horseradish peroxidase-conjugated secondary antibodies were applied, and enhanced chemiluminescence (Thermo, IL, USA) was used to visualize bands.

Evaluation of mRNA expression by real-time qPCR

To determine the gene expression profiles of kidney tissues, real-time qPCR was performed as previously described [19], to compare designated mRNA expression of obstructive kidneys in different groups. In brief, total RNA was extracted from the kidney cortexes using an RNA isolation kit (Qiagen, RNeasy Mini Kit). To ensure samples without genomic DNA contamination, total RNA was treated with DNase (Qiagen, RNase-Free DNase Set) and cDNA was synthesized using a Synthesis Kit (Bio-rad, USA). Total cDNA (1 μ l) was loaded in each well, mixed with PCR master mix (TaqMan Universal, Applied Biosystems, USA) and pre-designed primers (IDT, San Diego, USA) for TNF- α , IL-1 β , CXCL-1, MCP-1, TGF- β ₁, CTGF and Coll1 α 2, respectively (Listed in Table 1). The procedure for real-time qPCR included 2 min at 50°C, 15 min at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 55°C, and 30 s at 72°C (ABI PRISM 7900 HT; Applied Biosystems). Expression (evaluated as fold change for each target gene)




Figure 2. Inhibition of mTOR signaling by Rapamycin in UUO mice. UUO mice received daily i.p. injections of rapamycin (2 mg/kg of body weight) or vehicle respectively, starting 1 day prior to operation and continuing until termination of the experiment. A–H: Representative co-staining images of pS6K (red) and LTL (green) in UUO kidney sections with (E–H) or without (A–D) rapamycin treatment, from day 0 (A, E), day 3 (B, F), day 7 (C, G) and day 14 (D, H). Nuclei were labeled with DAPI (blue). Scale bar = 50 μ m. I: Representative western blot (panel left) and quantitative analysis (panel right) of pS6K expression in renal sections from vehicle-treated or rapamycin-treated UUO mice. *P<0.05, **P<0.01 vs. vehicle treated groups. Error bars represent S.E.

doi:10.1371/journal.pone.0033626.g002

was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, a housekeeping gene) following the well-established delta-delta method. All assays were performed in triplicate. In addition, a non-template control was included in the experiment to estimate DNA contamination of isolated RNA and reagents.

Data analysis

Statistical analysis was performed using the SPSS12.0 software package. Results were expressed as mean ± SE (standard error of mean). Differences among groups were tested by using One-Way ANOVA followed up with Tukey's test or t-test, as appropriate, and two-tailed p values are reported.




Figure 3. Rapamycin reduces tubulointerstitial injuries and collagen deposition in obstructed kidneys. Animals were treated as described above. A(A')–H(H'): Representative sections of vehicle (A–D:low power, inserted A'–D': high power) or rapamycin-treated (E–H: low power, inserted E'–H': high power) kidney with hematoxylin-eosin staining. Scale Bar: 200 µm. I–P: Representative costaining sections of obstructed kidneys with vehicle (M–P) or rapamycin (I–L) treatment, using anti-collagen I (red) and anti-LTL (green) as primary antibodies. Scale bar: 50 µm. Q–S: Quantitative assessment of tubular injuries (Q), interstitial infiltrates (R) and collagen-I deposition (S) in kidneys derived from UUO mice with or without administration of rapamycin. **P<0.01 vs. vehicle treated groups, NS no significance. n = 5 animals for each group. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g003

Results

Activation of mTOR signaling in kidney development and fibrogenesis

mTOR signaling highly activated, indicated by the expression of pS6K, in all kidney components (including renal parenchyma and interstitium) during the kidney development (Figure 1A(A')–B(B')), but declined to baseline in adult kidneys where its expression is mostly limited in small portion tubules (Figure 1C 6-week, Figure 1C' 16-month). The protein amount of pS6K and p-mTOR in the kidneys derived from post-natal mice was significantly higher than adult kidneys (left column in Figure 1J), indicating mTOR signaling is essential for kidney development (i.e. cells growth) and might have some basic physiological functions (i.e. protein synthesis) in adult kidneys. The expression of pS6K can be significantly induced by either ischemic (Figure 1D and middle column in Figure 1J) or obstructive injury (Figure 1G and right column in Figure 1J) immediately. The activation of mTOR signaling returned to normal level along with the recovery

of reversible kidney injury (Figure 1D–F and middle images in Figure 1J), but in irreversible obstructed nephropathy, activation of mTOR signaling kept increasing along with the progression of fibrosis (Figure 1G–I and right images in Figure 1J).

Improvement of kidney fibrosis by administration of rapamycin

Expression of pS6K (red) and specific proximal tubule marker Lotus tetragonolobus lectin (LTL, green) were determined by immunofluorescent staining. Significant activation of mTOR signaling was observed in dilated tubules and interstitium of obstructed kidneys, but little in glomeruli (Figure 2A–D). Rapamycin significantly suppressed expression of pS6K in injured kidneys (Figure 2E–H). Quantitative assessment of pS6K by western-blot further confirmed that activation of mTOR signaling was highly induced after kidney injury and reached the peak around 7-day post-obstruction, whereas administration of rapamycin resulted in a significant inhibition of pS6K expression (Figure 2I).




Figure 4. Rapamycin reduces proliferation in obstructed kidneys. Animals were treated as described in Methods. A(A')–F(F'): Representative sections from kidneys with [D(D')–F(F')] or without [A(A')–C(C')] rapamycin treatment, using anti-ki67 for immunohistochemistry. Ki67 positive cells are labeled with brown staining. High-power micrographs are presented as inserted images (A'–F'). Scale bar: 50 μ m. G–H: Quantitative analysis of Ki67+ tubular cells (G) and interstitial cells (H) in representative kidney sections. $n = 5$ animals for each group. ** $P < 0.01$ vs. vehicle-treated groups. NS no significance. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g004

Immunohistochemical analysis with HE staining revealed progressive tubular dilation tubules atrophy, interstitial infiltrates and matrix deposition in mouse obstructed kidneys (Figure 3A–D, A'–D': magnification of representative areas). Rapamycin markedly reduced these pathological changes. (Figure 3E–H and E'–H'). Co-staining of collagen-I and LTL showed that administration of rapamycin resulted in less collagen-I expression in the renal interstitium (Figure 3M–P), compared with the vehicle-treated group (Figure 3I–L). Quantitative analysis of kidney injury in UUO mice further confirmed that inhibition of mTOR signaling

by rapamycin remarkably improved tubular injury (Figure 3Q), interstitial infiltrates (Figure 3R) and collagen-I deposition (Figure 3S).

Rapamycin suppressed the proliferative activity of tubular and interstitial cells in obstructed kidneys

We analyzed the influence of rapamycin on the cells proliferation in fibrotic kidneys by immunohistochemical staining of anti-ki67 (brown). Only sporadic ki67-positive cells were observed in the normal kidneys of adult animals (Figure 4A–A').




Figure 5. Rapamycin attenuates inflammatory responses in obstructed kidneys. A–B: Immunofluorescent staining (A) and quantitative assessment (B) of F4/80+ macrophages in kidney sections from UUO mouse models. anti-F4/80 (green) was used to label macrophages in kidney tissues, costaining with DAPI (blue). Scale bar: 20 μ m. ** $P < 0.01$ vs. vehicle treated groups. n = 5 animals in each group. C–D: Immunohistochemical staining (C) and quantitative assessment (D) of CD3+ T cells in kidney sections from UUO mice. anti-CD3 was used to label T cells in the kidneys, counterstained with hematoxylin (blue). Representative areas were magnified in the inserted images(C). Scale bar: 50 μ m. * $P < 0.05$ vs. vehicle treated groups. n = 5 animals in each group. E–F: Analysis of proinflammatory (E) and fibrotic (F) profiles of kidney tissues from UUO models, using quantitative realtime-PCR. IL-1 β , TNF- α , CXCL-1 and MCP-1 were selected as pro-inflammatory chemokines for detection (E). ** $P < 0.01$, vs control group (sham operation); ## $P < 0.01$, rapamycin vs. vehicle treated groups; $^{\$}$ $P < 0.01$ vs U1d-vehicle group; $^{\$}$ $P < 0.01$ vs U3d-vehicle group. n = 5 animals in each group. TGF- β and CTGF were selected as fibrotic cytokines for detection (F). * $P < 0.05$, ** $P < 0.01$, vs control group (sham operation); # $P < 0.05$, ## $P < 0.01$ rapamycin vs vehicle-treated group. NS no significance, n = 5 animals in each group. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g005

However, a substantial increase of cell proliferation, including in tubules and interstitium, was induced by ureter obstruction (Figure 4B–C, B'–C'), in accordance with the activation of mTOR signaling. Administration of rapamycin resulted in a significant decrease of cell proliferation, as well as tubulointerstitial involvement, in the obstructed kidneys (Figure 4D–F and D'–F'). Quantitative assessment of cell counting further confirmed that proliferation in both tubular (Figure 4G) and interstitial cells (Figure 4H) was significantly suppressed in rapamycin groups.

The regulation of rapamycin on interstitial inflammatory cells during kidney fibrosis

Quantitative analysis by immunofluorescent and immunohistochemical staining revealed the marked infiltrates of F4/80+ macrophages (Figure 5A–B) and CD3+ T lymphocytes (Figure 5C–D) in obstructed kidneys since one day post obstruction, which aggravated along with the progression of interstitial fibrosis. Significantly, administration of rapamycin reduced the interstitial infiltrates of macrophages and T lymphocytes in obstructed kidneys (Figure 5A–D). Further examination with real-time qPCR revealed that obstructed kidneys developed progressive inflammatory responses, indicated by elevating the expression of multiple proinflammatory chemokines (IL-1 β , TNF- α , CXCL-1 and MCP-1) in a time-dependent manner post-obstruction, which was

dramatically reduced by rapamycin (Figure 5E). Real-time qPCR also revealed a lower expression of pro-fibrotic cytokines, including TGF- β ₁ and CTGF, in rapamycin treated groups (Figure 5F).

In UUO and IRI mouse models, large portion of infiltrated F4/80+ macrophages in interstitium highly expressed pS6K on day-1 after the initiation of kidney injury (Figure 6A–A'' and Figure 6B–B''', representative cells indicated by white arrows). The obstructed kidneys also featured progressive infiltrates of CD4+ T cell and neutrophils, however, little expression of pS6K was observed in either CD4+ T cells (Figure 6C–E) or neutrophils (Figure 6F) in UUO mice. Therefore, the activation pattern of mTOR signaling in kidney inflammatory cells, revealed by immunoreactivity assessment, indicated that macrophages, instead of CD4+ T cells or neutrophils, may be direct targets of rapamycin in its anti-inflammation effects.

To further confirm whether the mTOR signaling really regulates the activity of macrophages in the initiation of kidney fibrosis, we isolated macrophages from both vehicle (Figure 7A–A'') and rapamycin-treated (Figure 7B–B'') kidneys on day-1 post-obstruction and characterized their mRNA profiles of inflammatory chemokines, including IL-1 β , TNF- α and MCP-1. Real-time qPCR analysis revealed that macrophages from rapamycin-treated groups presented much less inflammatory activity than vehicle groups (Figure 7C).




Figure 6. Activation profiles of mTOR signaling in the interstitial inflammatory cells. Kidney sections derived from either UUO or IRI models were analyzed by immunohistochemistry using antibodies against pS6K, F4/80, CD4 or anti-neutrophil. A–A'' and B–B''': Expression of pS6K (red) is immediately induced in F4/80+ macrophages (green) after kidney injury. Large portions of interstitial macrophages in obstructed kidney (A–A'') and IRI kidney (B–B'') are co-stained with F4/80 and pS6K (indicated by arrows). C–E: Co-staining of CD4 (green) and pS6K in obstructed kidneys. F: Costaining of anti-neutrophil and pS6K in obstructed kidneys. Scale bar: 20 μ m. doi:10.1371/journal.pone.0033626.g006




Figure 7. Rapamycin inhibits inflammatory activity of macrophages isolated from obstructed kidneys. A–B: Co-immunostaining images of kidney sections from day-1 post-obstruction with administration of rapamycin (A–A'') or vehicle (B–B''), using anti-pS6K (red), anti-F4/80 (green) and DAPI (blue) for immunofluorescent staining. Representative areas in A' and B' (indicated by white square) are magnified in A'' and B'', respectively. Scale bar: 50 μ m. C. Assessment of inflammatory activity of isolated macrophages from obstructed kidney on day-1 post-operation. mRNA level of proinflammatory chemokines, including TNF- α , IL-1 β and MCP-1, were determined by realtime-PCR. * $P < 0.05$, ** $P < 0.01$, vs control group (sham operation); # $P < 0.05$, ## $P < 0.01$ vs vehicle-treated group. $n = 5$ animals in each group. Ctrl: control group, U1d-Ve: 1-day post UUO operation with administration of vehicle, U1d-Rp: 1-day post UUO operation with administration of rapamycin. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g007

The inhibition on the activation of myfibroblasts by rapamycin

In normal kidney, α SMA expression was only observed in arteries and arterioles (Figure 8A–A'' indicated by arrow-head). Low expression of pS6K was found in tubules and sporadic interstitial cells but little overlapped with the α SMA (Figure 8A–A''). However, activation of fibroblasts and mTOR signaling were markedly induced on day-1 post ureteral obstruction, indicating by de novo expression of α SMA and pS6K within the interstitium (Figure 8B–B'). Merged images showed the co-expression of α SMA and pS6K in a large portion of interstitial myfibroblasts (Figure 8B'–B''). Representative areas (Figure 8C–C'') were magnified to further confirm the expression of pS6K in active myfibroblasts (white arrow), but not in arterial cells (asterisk). In rapamycin treated group, the expression of α SMA and pS6K in obstructed kidneys was significantly suppressed (Figure 8D–D''). Given the pivotal role of TGF- β_1 in kidney fibrosis, we further investigated the effect of rapamycin on TGF- β_1 -induced myfibroblast activation. NIH3T3 cells cultured in regular condition slightly expressed α SMA and pS6K (Figure 8E–E''). Stimulation of TGF- β_1 in NIH3T3 cells

resulted in marked expression of α SMA and pS6K (Figure 8F–F''), which was significantly suppressed by rapamycin (Figure 8G–G''). Western blot analysis further confirmed these changes (Figure 8H–I).

To further evaluate the effect of mTOR signaling on myfibroblasts transition, we quantify α SMA and vimentin expression in obstructed kidney using immunohistochemical staining and western blot analysis. In sham-operated kidney, α SMA was found only in arteries and arterioles. However, along with the progression of interstitial fibrosis in obstructed kidneys, substantial accumulation of α SMA was found increasing within the interstitium. The amount of α SMA deposition and renal histological changes were significantly ameliorated in rapamycin-treated kidneys (Figure 9A), indicating inhibition of mTOR signaling markedly reduced myfibroblasts activation. Co-staining of vimentin (red) and LTL (green) further revealed the progressive accumulation of vimentin in the interstitium as a hallmark of fibrotic kidneys, which could be significantly attenuated by rapamycin (Figure 9B). Western blot of kidney lysates further confirmed that inhibition of mTOR signaling by rapamycin markedly reduced α SMA and vimentin production in UUO mice.







Figure 8. Rapamycin suppresses activation of mTOR signaling in active myofibroblasts. Immunofluorescent staining of kidney sections derived from UO models on day-1 post-obstruction was performed, using anti- α SMA (green, A–D) and anti-pS6K (red, A'–D'). Images were merged (A''–D'') and co-labeled with DAPI (A'''–D'''). Representative areas in B–B''' (white square) were magnified in C–C'''. Arrow heads (A–A''') and asterisks (C–C''') indicate arterioles in the kidneys. Arrows indicate representative myofibroblasts expressing pS6K (C–C'''). Scale bar: 50 μ m. NIH3T3 cells were cultured for 24 hours in the absence (E–E'') or presence of 20 ng/ml recombinant human TGF- β 1 (F–F'', G–G''), with administration of vehicle (F–F'') or rapamycin (G–G''). The cells were stained for α SMA (green) and pS6K (red). DAPI was used to stain the nuclei. Magnification was 400 \times . (H–I): Representative Western blot and quantitative assessment for expression of α SMA and pS6K in NIH3T3 cells. β -actin was used in this experiment to control for equal protein loading. * P <0.05, ** P <0.01 vs. control groups. # P <0.05, ### P <0.01 vs. TGF- β +vehicle groups. Error bars represent S.E. doi:10.1371/journal.pone.0033626.g008

The effect of rapamycin on fibrogenic phenotype of tubular epithelial cells

To determine whether the tubular epithelial cells remain potential targets of rapamycin in the progression of renal fibrosis, we studied the relationship between tubular fibrogenic activity and mTOR signaling. Kidney Injury Molecule-1 (Kim-1) was markedly up-regulated in either obstructed (Figure 10A) or ischemic kidneys (Figure 10B), where it localized to the apical surface of injured proximal tubule epithelial cells. These surviving epithelial cells, indicated by Kim-1 staining, were surrounded by abundant interstitial α SMA-positive myofibroblasts (Figure 10A) and CD11b-positive macrophages (Figure 10B), which revealed profibrogenic and proinflammatory roles of active epithelial cells after kidney injury. However, few Kim-1 positive epithelial cells co-expressed pS6K, although these tubules was surrounded by pS6K-positive interstitial cells (Figure 10C), indicating the mTOR signaling may play little role in the fibrogenic pathway conducted by active epithelial cells.

To further determine whether rapamycin could functionally affect the fibrogenic phenotype of epithelial cells, we examined the effect of rapamycin on the generation of profibrotic factors in cultured HK2 cells after exposure to aristocholic acid (AA). Immunocytochemistry confirmed that rapamycin markedly inhibited the proliferation and mTOR signaling in cultured HK2 cells (Figure 10D). AA treatment for 48 hr resulted in marked upregulation of CTGF and collagen-I in HK2 cells. Administration of rapamycin significantly inhibited pS6K expression but had little effect on the production of above fibrotic factors (Figure 10E). Real-time qPCR results confirmed that AA treatment induced the activation of fibrogenic and proinflammatory genes in HK2 cells, including TGF- β 1, CTGF, Col1 α 2 and MCP-1. Administration of rapamycin did not improve the fibrogenic and inflammatory phenotype of HK2 cells, induced by AA treatment (Figure 10F).

Discussion

Although the inhibitory effect of rapamycin on renal fibrosis has been reported in previous studies [1,2], little was elucidated upon its cellular targets and regulatory mechanism. This study, for the first time, clarified that which cell types have mTOR activation in renal fibrosis and where rapamycin works on to protect the kidney.

Infiltration of inflammatory cells has long been established as an early and characteristic feature of renal fibrosis in virtually all situations [20]. We suggested that mTOR signaling might play an important role in the initiation and progression of kidney inflammation. To test this hypothesis, we characterized the activation profiles of mTOR signaling in different inflammatory cells types, including macrophages, CD4+ lymphocytes and neutrophils. Activation of mTOR and significant inflammatory response were induced in infiltrated macrophages post ischemic or obstructed injury, which could be significantly blocked by rapamycin (Figure 6 and Figure 7). Interestingly, little expression of pS6K was observed in either CD4+ lymphocytes or neutrophils in UO mice, although rapamycin reduced the infiltrates of those

inflammatory cells in the kidneys (Figure 5 and Figure 6). Therefore, the activation pattern of mTOR signaling in kidney inflammatory cells, revealed by immunoreactivity assessment, indicated that interstitial macrophages, instead of CD4+ T cells or neutrophils, might be direct targets of rapamycin. As multiple studies suggested that rapamycin presented a paradoxical aspect in regulating T cells immunobiology, depending on the subgroups of targeted T cell [21] and the conditions under which T cells are stimulated [22], it is difficult to conclude the role of rapamycin in regulating T cells in fibrotic kidneys based on our current observation. Furthermore, future experiments are also necessary to elucidate the role of mTOR signaling in the subgroups of macrophages, as macrophages present totally different phenotypes during kidney injury and repair progress, depending on the local inflammatory milieu [9,23] and rapamycin might accordingly have different regulatory effects on them.

The presence of activated myofibroblasts is considered as a hallmark of kidney fibrosis in CKD [10]. In our study, colocalization of pS6K and α SMA in fibrotic kidneys revealed the activation of mTOR signaling in interstitial myofibroblasts, which was also supported by the experiment of TGF- β 1 induced transition of fibroblasts into myofibroblasts (Figure 8). We further confirmed that the expression of α SMA and vimentin in obstructed kidney were significantly ameliorated in rapamycin-treated kidneys (Figure 9), indicating inhibition of mTOR signaling markedly reduced myofibroblasts activation. Taken together, our studies revealed that rapamycin could ameliorate renal fibrosis by inhibiting the mTOR signaling in activated myofibroblasts.

Recently, emerging evidence indicated that tubular epithelial cells had an active role in the progression of renal fibrosis via generation of various proinflammatory and profibrotic factors, including cytokines, growth factors and matrix proteins [8,24,25]. To determine whether rapamycin protects the kidney from fibrosis partly by inhibiting the fibrogenic role of tubular epithelial cells, we labeled the surviving proximal tubules in both obstructed and ischemic kidneys, using anti-Kim-1, which has been widely identified as a sensitive and specific biomarker for injured proximal epithelial cells [26,27]. After kidney injuries, significant infiltration of myofibroblast and macrophage was observed around the Kim-1 positive tubules (Figure 10 A–B), indicating surviving tubular epithelial cells recruited these effector cells and contributed to the interstitial fibrosis. However, little pS6K expression could be detected in the active tubular epithelial cells (Figure 10C), suggesting that mTOR signaling has not been activated in the fibrogenic epithelial cells. To further assess the effect of rapamycin on epithelial fibrogenesis, we established a cellular fibrotic model with HK2 cells secondary to AA exposure, which has been widely used to induce kidney interstitial fibrosis [28–30]. HK2 cells with AA treatment showed increased activity in pro-fibrogenesis and pro-inflammation, indicating by elevated protein and mRNA levels of TGF- β 1, CTGF, Collagen-1 and MCP-1, but these levels were not lowered down by rapamycin (Figure 10E–F), providing further evidence that rapamycin does not directly block the fibrogenic activity of tubular epithelial cells during the progression of kidney interstitial fibrosis.




Figure 9. Assessment of myofibroblasts activation in obstructed nephropathy. Animals were treated as described in Methods and Materials. A. Representative sections of vehicle or rapamycin-treated kidneys stained with anti- α SMA by immunohistochemistry. Scale bar: 100 μ m. B. Representative confocal images of vehicle or rapamycin-treated kidneys costained with anti-vimentin (red) and anti-LTL(green). Scale bar: 100 μ m.

C–F: Representative western blot and densitometric analyses for α SMA (C–D) and vimentin (E–F) expression in UUO kidneys. β -actin was used in this experiment to control for equal protein loading. Data were presented as mean \pm S.E.M. n=5 animals in each group. *P<0.05, **P<0.01 vs. vehicle-treated groups. NS no significance. Error bars represent S.E.
doi:10.1371/journal.pone.0033626.g009

Activation of mTOR within the kidney has been reported in different kinds of kidney diseases, including acute ischemic injury [31], polycystic kidney disease [32,33], diabetic nephropathy [34,35] and other causes of progressive kidney disease [2,36]. Although the overall effects of mTOR inhibitors on glomerular hypertrophy, interstitial inflammation and fibrosis, prove to be protective in CKD, the different function that mTOR signaling

acts in acute and chronic kidney injury are significant [31,37]. In this study, we observed the different expression pattern of mTOR signaling between reversible IRI and progressive fibrotic models (Figure 1), which indicated the induction of mTOR activation after kidney injury might therefore serve a dual purpose. Firstly, it is able to activate the innate immune effector cells at the early stage of injury, such as macrophages, which thereby clear




Figure 10. Rapamycin has little effect on the fibrogenic phenotype of tubular epithelial cells. HK2 cells or Animals were treated as described in Methods and Materials. A–C. Representative immunofluorescent costaining images of kidney sections derived from UUO mice or IRI mice, using anti-Kim-1 and anti- α SMA (A), anti-Kim-1 and anti-CD11b (B), anti-pS6K and anti-Kim-1 (C). Nuclei were labeled with DAPI (blue). Scale bar: 50 μ m. D. HK2 cells were cultured for 48 hours in the absence or presence of aristolochic acid (AA), with or without administration of rapamycin. The cells were stained for Ki67 or pS6K. DAPI was used to stain the nuclei. E. Representative western blot and densitometric analyses for expression of CTGF, Collagen-I, and pS6K in cultured HK2 cells. β -actin was used in this experiment for equal protein loading control. Data were presented as mean \pm SE. ** P<0.01, NS no significance. F. Assessment of proinflammatory and profibrogenic gene expression in culture HK2 cells. mRNA level of MCP-1, TGF- β , CTGF and Collagen-I were determined by realtime-PCR. ** P<0.01, NS no significance. Error bars represent S.E.
doi:10.1371/journal.pone.0033626.g010

apoptotic cells and debris at a site of tissue damage. Secondly, persistent mTOR activation in these effectors at an extended stage of injury, however, might be maladaptive by promoting chronic inflammation and ultimately renal fibrosis. Therefore, the balance of mTOR signaling activation could be a key to control the outcome of kidney injuries. Our data are in accordance with the current views that tightly balanced mTOR activity is required in kidney homeostasis and the role of rapamycin in kidney diseases is context dependent [1,38].

In conclusion, this study confirmed the interstitial macrophages and myofibroblasts as the cellular targets of rapamycin for its protection of kidney fibrosis. Suppression of mTOR signaling in active macrophages and myofibroblasts leads to amelioration of kidney inflammation and fibrosis. A better understanding of the

underlying mechanisms of mTOR signaling in renal fibrosis might help to find out a way to halt the fibrotic progression.

Acknowledgments

We are very grateful to Dr. Jun Li and Dr. Yinghong Liu for useful discussion on this manuscript preparation. We also thank Dr. Xun Zhou and Dr. Xiang Zhou for the technical guidance in the animal experiments.

Author Contributions

Conceived and designed the experiments: GC FL. Performed the experiments: GC HC CW. Analyzed the data: GC HC YP LS. Contributed reagents/materials/analysis tools: HL. Wrote the paper: GC. Revised the manuscript: FL.

References

- Huber TB, Walz G, Kuehn EW (2011) mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. *Kidney Int* 79: 502–511.
- Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, et al. (2006) Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. *Kidney Int* 69: 2029–2036.
- Lieberthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. *J Am Soc Nephrol* 20: 2493–2502.
- Lock HR, Sacks SH, Robson MG (2007) Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. *Am J Physiol Renal Physiol* 292: F76–81.
- Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, et al. (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. *J Am Soc Nephrol* 16: 2063–2072.
- Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, et al. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-1 receptor and Mammalian target of rapamycin. *Am J Pathol* 170: 301–315.
- Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, et al. (2008) Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. *Am J Physiol Renal Physiol* 294: F440–449.
- Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV (2010) Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. *Nat Med* 16: 535–543, 531p following 143.
- Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, et al. (2008) Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. *J Pathol* 214: 104–113.
- Strutz F, Zeisberg M (2006) Renal fibroblasts and myofibroblasts in chronic kidney disease. *J Am Soc Nephrol* 17: 2992–2998.
- Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. *Genes Dev* 18: 1926–1945.
- Lee DF, Hung MC (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. *Cell Cycle* 6: 3011–3014.
- Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 130: 440–455.
- Shegogue D, Trojanowska M (2004) Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. *J Biol Chem* 279: 23166–23175.
- Wang S, Wilkes MC, Leof EB, Hirschberg R (2010) Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. *Am J Physiol Renal Physiol* 298: F142–149.
- Winbanks CE, Grimwood L, Gasser A, Darby IA, Hewitson TD, et al. (2007) Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. *Int J Biochem Cell Biol* 39: 206–219.
- Guo G, Morrissey J, McCracken R, Tolley T, Klahr S (1999) Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. *Am J Physiol* 277: F766–772.
- Ichimura T, Asselton EJ, Humphreys BD, Gunaratnam L, Duffield JS, et al. (2008) Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. *J Clin Invest* 118: 1657–1668.
- Liu FY, Li XZ, Peng YM, Liu H, Liu YH (2008) Arkadia regulates TGF-beta signaling during renal tubular epithelial to mesenchymal cell transition. *Kidney Int* 73: 588–594.
- Harris RC, Neilson EG (2006) Toward a unified theory of renal progression. *Annu Rev Med* 57: 365–380.
- McMahon G, Weir MR, Li XC, Mandelbrot DA (2011) The evolving role of mTOR inhibition in transplantation tolerance. *J Am Soc Nephrol* 22: 408–415.
- Ferrer IR, Araki K, Ford ML (2011) Paradoxical aspects of rapamycin immunobiology in transplantation. *Am J Transplant* 11: 654–659.
- Anders HJ, Ryu M (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. *Kidney Int*.
- Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. *Nat Rev Nephrol* 7: 684–696.
- Yang L, Humphreys BD, Bonventre JV (2011) Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. *Contrib Nephrol* 174: 149–155.
- Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, et al. (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. *J Biol Chem* 273: 4135–4142.
- Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. *Am J Physiol Renal Physiol* 290: F517–529.
- Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, et al. (2008) Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. *Kidney Int* 73: 595–607.
- Zhou L, Fu P, Huang XR, Liu F, Chung AC, et al. (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. *Am J Physiol Renal Physiol* 298: F1006–1017.
- Yang L, Li X, Wang H (2007) Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. *Nephrol Dial Transplant* 22: 445–456.
- Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS (2006) Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. *Transplantation* 82: 17–22.
- Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. *Proc Natl Acad Sci U S A* 103: 5466–5471.
- Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. *J Am Soc Nephrol* 21: 489–497.
- Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, et al. (2006) Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. *J Am Soc Nephrol* 17: 1395–1404.
- Chen JK, Chen J, Thomas G, Kozma SC, Harris RC (2009) S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. *Am J Physiol Renal Physiol* 297: F585–593.
- Dickmann F, Rovira J, Carreras J, Arellano EM, Banon-Maneus E, et al. (2007) Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. *J Am Soc Nephrol* 18: 2653–2660.
- Lieberthal W, Fuhro R, Andry CC, Renne H, Abernathy VE, et al. (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. *Am J Physiol Renal Physiol* 281: F693–706.
- Fogo AB (2011) The targeted podocyte. *J Clin Invest* 121: 2142–2145.